GPC3 and hepatocellular carcinoma: Several therapeutic monoclonal antibodies targeting GPC3 have been developed, such as GC33, which has demonstrated antibody-dependent cell-mediated cytotoxicity against GPC3-positive hepatocellular carcinoma (HCC) cell lines and inhibition of tumor growth in mouse models of HCC [108].